RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.840
-0.030 (-3.46%)
At close: Apr 28, 2026, 4:00 PM EDT
0.840
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$66,059
Profits / Employee
-$656,941
Market Cap
37.84M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| Sensei Biotherapeutics | 15 |
RNXT News
- 5 days ago - RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 14 days ago - Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - GlobeNewsWire
- 20 days ago - RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - GlobeNewsWire
- 27 days ago - RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - GlobeNewsWire
- 4 weeks ago - RenovoRx Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment - GlobeNewsWire
- 5 weeks ago - RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - GlobeNewsWire